Literature DB >> 28874314

Drug discovery for the treatment of substance use disorders: novel targets, repurposing, and the need for new paradigms.

Cristiano Chiamulera1, Laura Padovani2, Mauro Corsi3.   

Abstract

Drug addiction treatment medications available nowadays are limited in both efficacy and number. The increased understanding of drug addiction circuitries leads the scientific community to look for better molecules and targets for detoxification and relapse prevention. This review focus on known targets (e.g., metabotropic glutamate receptor 5 and GABAB receptor) and on novel potential treatment acting on oxytocin system, which interacts with diverse neurotransmitters, has proved successful in both preclinical and clinical studies on ethanol, cocaine and methamphetamine. A crucial issue is the identification of new investigational paradigms, which may help to predict treatment efficacy and improve effectiveness.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28874314     DOI: 10.1016/j.coph.2017.08.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  3 in total

Review 1.  Epigenetic pharmacotherapy for substance use disorder.

Authors:  Gregory C Sartor
Journal:  Biochem Pharmacol       Date:  2019-07-12       Impact factor: 5.858

Review 2.  Functional Neurocircuits and Neuroimaging Biomarkers of Tobacco Use Disorder.

Authors:  Matthew T Sutherland; Elliot A Stein
Journal:  Trends Mol Med       Date:  2018-02       Impact factor: 11.951

3.  Untargeted Metabolomic Analysis of Rat Neuroblastoma Cells as a Model System to Study the Biochemical Effects of the Acute Administration of Methamphetamine.

Authors:  Garth L Maker; Tobias Green; Ian Mullaney; Robert D Trengove
Journal:  Metabolites       Date:  2018-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.